Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363181 | 0.87 | CRHR1 (0.54) | ADORA3CRHR1MTNR1AMAPTMPO | |
| SCHEMBL5353273 | 0.79 | CRHR1 (0.54) | ADORA3CRHR1MAPTKDM4EALDH1A1 | |
| SCHEMBL5360027 | 0.76 | CRHR1 (0.49) | ADORA3CRHR1MAPT | |
| SCHEMBL5351554 | 0.72 | CRHR1 (0.55) | ADORA3CRHR1MAPTCSNK2A1ALPL | |
| SCHEMBL5357818 | 0.72 | CRHR1 (0.52) | ADORA3CRHR1LMNAMAPT | |
| SCHEMBL5360029 | 0.69 | CRHR1 (0.42) | ADORA3CRHR1POLB | |
| SCHEMBL6678654 | 0.69 | CYP1A1 (0.58) | ADORA3CRHR1LMNAMAPTKDM4E | |
| SCHEMBL28028759 | 0.69 | MTNR1A (0.59) | MTNR1AALDH1A1MEN1POLBKMT2A | |
| SCHEMBL6283374 | 0.67 | CRHR1 (0.71) | ADORA3CRHR1LMNAALDH1A1 | |
| SCHEMBL5351558 | 0.67 | CRHR1 (0.60) | ADORA3CRHR1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169790-B2 | 5-substituted 2-aryl-4-pyrimidinones | NEUROGEN CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050234051-A1 | 5-Substituted 2-aryl-4 pyrimidinones | NEUROGEN CORPORATION (US) | 2005-10-20 | — | — | US | disclosed |
| US-6943173-B2 | 5-substituted 2-aryl-4-pyrimidinones | NEUROGEN CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1301490-A2 | 5-SUBSTITUTED 2-ARYL-4-PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020052387-A1 | 5-Substituted 2-aryl-4-pyrimidinones | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| WO-2002006242-A2 | 5-SUBSTITUTED 2-ARYL-4-PYRIMIDINONES | NEUROGEN CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052387-A1 | 5-Substituted 2-aryl-4-pyrimidinones | CRHR1, CRHR2, HTR4 | ADORA3 268/4885CRHR1 1/4885MTNR1A 108/4885 |
| US-20050234051-A1 | 5-Substituted 2-aryl-4 pyrimidinones | CRHR1, CRHR2, HTR4 | ADORA3 242/4885CRHR1 1/4885MTNR1A 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.